Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
Phase II Clinical Study to Evaluate the Efficacy and Safety of Teniposide as a Post-Line Therapy for c-Myc-Driven Extensive-Stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
15 participants
Feb 7, 2025
INTERVENTIONAL
Conditions
Summary
The study is being conducted to investigate the efficacy and safety of teniposide in patients with extensive-stage small cell lung cancer who have failed standard treatment and with high expression of the c-Myc-driven FBXW2/MYC gene. Based on the results, the study will explore the correlation between the expression of FBXW2/MYC and the efficacy of teniposide.
Eligibility
Inclusion Criteria7
- extensive stage small cell lung cancer
- Progression after receiving at least one chemotherapy drug treatment in the past;
- ECOG score 0-1
- c-Myc-driven
- Expected survival period ≥3 months
- Age: 18-75 years old;
- The informed consent form complies with the ICH-GCP principles.
Exclusion Criteria5
- No measurable lesions
- Other severe and persistent diseases or organ system dysfunction;
- Women planning pregnancy or men planning family planning;
- Women who are pregnant or breastfeeding;
- Those who cannot follow the research protocol provided by the investigator.
Interventions
Teniposide administration: 60mg/m2, diluted with 500ml of 0.9% sodium chloride injection before use, intravenous infusion for more than 1 hour, for 3-5 consecutive days, with 21 days as one cycle of treatment.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06758700